Lung-MAP
@LungMAP
A lung cancer precision medicine trial and unique partnership of @theNCI @CancerResrch @FNIH_org and @SWOG Testing new treatments, including immunotherapies.
Lung-MAP 3.0’s easier genetic screening process means @LungMAP will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S. lung-map.org @FNIH_Org @CancerResrch @SWOG @theNCI
Thank you to Marcia Horn, representing @METCrusaders (and @SWOG patient advocate) for sharing her insights & wisdom in the @LungMAP webinar "Advocating, Accelerating, and Amplifying Lung Cancer Discovery." Recording is at bit.ly/43cRtzo
A recording of the May 14th @LungMAP Advocacy Webinar is online at bit.ly/43cRtzo. Featuring a panel discussion with @CancerResrch's Ryan Hohman, @LUNGevity's @aesfCEO, Marcia Horn of @Exon20Group & @WarOnCancer, and @lcfamerica's Kim Norris. #lcsm #lungcancer @SWOG
The @ASCOPost discusses #ASCO25 presentations on S2302 Pragmatica-Lung, a groundbreaking phase 3 trial launched based on findings of phase 2 @LungMAP sub-study S1800A. #NSCLC #lcsm
Thanks to @ASCOPost for highlighting the lessons for #clinicaltrials that have come from this study, presented at #ASCO25: SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC ascopost.com/news/june-2025…
A recording of the May 14th @LungMAP Advocacy Webinar is online at bit.ly/43cRtzo. Featuring a panel discussion with @CancerResrch's Ryan Hohman, @LUNGevity's @aesfCEO, Marcia Horn of @Exon20Group & @WarOnCancer, and @lcfamerica's Kim Norris. #lcsm #lungcancer @SWOG
Advancements in clinical trials have enabled therapies to become first-line treatments. In the last 15 years, clinical trials have been the gold standard. Watch the @LungMAP Advocacy Webinar live at bit.ly/43cRtzo. #lcsm #lungcancer
Lung MAP annual update at ASCO25 -Meeting the "unmet needs" with 3 active trials in MET space. @LungMAP @theNCI @FNIH_Org
@ChristianRolfo presenting at @LungMAP Annual Update at #ASCO25 the S1900J trial for patients with #NSCLC and #METamplification as primary driver treated with Amivantab sc. @SWOG @FNIH_Org @OhioStateMedOnc @OSUCCC_James @ASCO @ShirishGadgeel @drgandara @rolfolab
Great to see results from @LungMAP S1900E 📍Despite smaller subgroups, it’s quite clear that the cohort with STK11 co mutation does not respond as well with sotorasib. Congratulations to Dr.Padda and team. #lcsm #ASCO25
S1800E is a @LungMAP non-match sub-study. Randomized ph 2/3: docetaxel & ramucirumab w or w/o cemiplimab in patients w previous platinum-based chemo & IO for stage IV or recurrent NSCLC. PI: Saima Waqar, MD, MSCI @WashUOncology @SitemanCenter
Pragmatica-Lung has effectively reduced barriers to clinical trial participation and decreased clinical trial staff burden, showing its efficacy as a potential model for future studies. New findings announced at #ASCO25: asco.org/abstracts-pres…
#ASCO25 @SWOG S2302 Pragmatica-Lung in adv non-small cell #lungcancer reports ramucirumab + pembrolizumab did not extend survival. Study is a model for large trials that launch quickly, are easy to conduct, rapidly enroll a highly representative population swog.org/news-events/ne…
Monday is a busy day for @SWOG at #ASCO25, with presentations on results from #lungcancer studies S1914, @LungMAP S1900E, and S2302 Pragmatica-Lung! Full list is at swog.org/sites/default/…
Lung MAP annual update @ASCO this morning. Mary Redman starts with a slide showing the "evolution of this public-private partnership, now with completion of 16 trials. @ReckampK @theNCI @FNIH_Org @CancerResrch @SWOG
@ChristianRolfo presenting at @LungMAP Annual Update at #ASCO25 the S1900J trial for patients with #NSCLC and #METamplification as primary driver treated with Amivantab sc. @SWOG @FNIH_Org @OhioStateMedOnc @OSUCCC_James @ASCO @ShirishGadgeel @drgandara @rolfolab
Starting the #ASCO25 meeting with @LungMAP Annual Update. A fantastic research group! Mary Redman, @ReckampK @drgandara @ShirishGadgeel @DrRoyHerbstYale @LealTiciana Sara Goldberg @CoreyLangerMD @SaiamaWaqar @SWOG @NIH
Results from @LungMAP sub-study S1900E will be presented as a rapid oral abstract (8515) at #ASCO25 on Mon, June 2, 9:00am CT, by @SukiPaddaMD. Abstract is at meetings.asco.org/abstracts-pres…. #LCsm @CancerResrch @FNIH_Org @ReckampK @drgandara
#ASCO25 @ASCO #NSCLC #LCSM S1900E (Abstract 8518): Sotorasib efficacy by co-mutations in previously treated KRAS G12C-mut NSCLC: • 🎯 ORR: 35% (TP53 co-mut) vs 16% (STK11 co-mut) • 📊 Disease control rate: 78% vs 60% • ⏳ Median PFS: 5.7 vs 4.1 months • 🕒 Median OS: 18.2…
2025 @LungMAP Advocacy Webinar Trial updates + wisdom from #lungcancer advocacy org leaders: what's needed to advance treatments & better meet patient needs. #lcsm THANK YOU @BFallerMD @lcfamerica @LUNGevity @WarOnCancer @met_crusaders! Recording: youtube.com/watch?v=sFQh17…
Many states, such as Louisiana and Illinois, are requiring insurance companies to cover cancer biomarker testing. Watch the Advocacy Webinar live and on-demand for @LungMAP updates: bit.ly/43cRtzo #lcsm #biomarkertesting
.@LungMAP allows patients to be enrolled in clinical trials conducted at small sites, which leads to better outcomes. Watch the webinar live and on-demand: bit.ly/43cRtzo #lcsm #luncancer
Starting now! @LungMAP Advocacy Webinar: Advocating, Accelerating, and Amplifying Lung Cancer Discovery. Join the live webinar: bit.ly/3EpG5Yx. #lcsm #lungcancer
#EAOnc Spring25 Meeting @LealTiciana @WinshipAtEmory provides update on @LungMAP 3.0- Biomarker Driven Master Protocol now with 10+ yrs of experience. We continue to have this #precisionmedicine trial opened @SylvesterCancer @eaonc
TOMORROW: @LungMAP Advocacy Webinar Wed., May 14, 1-2 pm ET 1-hr webinar will review the trial's recent evolution & will engage advocacy partners in discussion to paint a clearer picture of current and emerging patient needs in #NSCLC. @theNCI Register at: friendsofcancerresearch.org/event/lung-map…
